Diamyd Medical AB (OSTO:DMYD B) Tariff Resilience Score : 5/10 (As of Jul. 18, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Tariff Resilience Score?

Diamyd Medical AB has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Diamyd Medical AB has Diamyd Medical's pharmaceutical focus involves international clinical trials and partnerships, exposing it to some tariff risks. However, its primary revenue is not heavily reliant on imports/exports. Historical tariffs have had limited impact, but future regulatory changes could pose challenges.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Diamyd Medical AB might have Average Resilient.

Competitive Comparison of Diamyd Medical AB's Tariff Resilience Score

For the Biotechnology subindustry, Diamyd Medical AB's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB's Tariff Resilience Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Tariff Resilience Score falls into.

Save Embed

;

Save Embed

;

Diamyd Medical AB (OSTO:DMYD B) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score	Resilience Level
7 - 10	Highly Resilient
4 - 6	Average Resilient
0 - 3	Highly Vulnerable

Diamyd Medical AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Tariff Resilience Score

Comparable Companies

Traded in Other Exchanges

DYMDF:USA

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines